
New Data Shows Sustained Efficacy of Roche’s Susvimo in Two Serious Diabetic Eye Conditions
Roche announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for treating diabetic macular edema (DME) and diabetic retinopathy (DR), the leading causes of vision loss in adults with diabetes.…











